Physician profile
Thomas Robert Neumann
NPI 1841271574
$159.93
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $33.65 | 2019 | |
| Visionrt, INC. | $22.31 | 2019 | |
| Abbvie INC. | $19.72 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $18.07 | 2019 | |
| Seagen INC. | $14.62 | 2019 | |
| Jazz Pharmaceuticals INC. | $14.49 | 2019 | |
| Verastem, INC. | $13.04 | 2019 | |
| Eisai INC. | $12.23 | 2019 | |
| Genzyme Corporation | $11.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Neumann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.